Copyright ©The Author(s) 2023.
World J Respirol. May 26, 2023; 12(1): 1-9
Published online May 26, 2023. doi: 10.5320/wjr.v12.i1.1
Figure 1
Figure 1 Contraindications of monoclonal antibody therapy. COVID-19: Coronavirus disease 2019.
Figure 2
Figure 2 High-risk groups indicated for treatment with monoclonal antibodies. CVD: Cardiovascular disease; HTN: Hypertension; COPD: Chronic obstructive pulmonary disease; BMI: Body mass index; CKD: Chronic kidney disease.